Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anthony Zietman, M.D., M.B.,B.S.

Co-Author

This page shows the publications co-authored by Anthony Zietman and Jason Efstathiou.
Connection Strength

7.728
  1. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer. 2013 Apr 02; 108(6):1225-30.
    View in: PubMed
    Score: 0.531
  2. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr; 61(4):705-11.
    View in: PubMed
    Score: 0.485
  3. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J. 2009 Jul-Aug; 15(4):312-8.
    View in: PubMed
    Score: 0.411
  4. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1302-8.
    View in: PubMed
    Score: 0.374
  5. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230.
    View in: PubMed
    Score: 0.190
  6. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415.
    View in: PubMed
    Score: 0.181
  7. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03.
    View in: PubMed
    Score: 0.180
  8. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 2017 Jul; 6(7):1827-1836.
    View in: PubMed
    Score: 0.178
  9. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960.
    View in: PubMed
    Score: 0.173
  10. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60.
    View in: PubMed
    Score: 0.173
  11. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133.
    View in: PubMed
    Score: 0.171
  12. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1028-1036.
    View in: PubMed
    Score: 0.169
  13. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):722-728.
    View in: PubMed
    Score: 0.169
  14. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 01; 32(34):3801-9.
    View in: PubMed
    Score: 0.149
  15. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56.
    View in: PubMed
    Score: 0.143
  16. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):618-23.
    View in: PubMed
    Score: 0.141
  17. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.139
  18. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. Curr Opin Urol. 2013 Sep; 23(5):429-34.
    View in: PubMed
    Score: 0.137
  19. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013 Aug; 11(8):952-60.
    View in: PubMed
    Score: 0.136
  20. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May; 9(3):e90-5.
    View in: PubMed
    Score: 0.134
  21. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013 Apr; 14(2):109-15.
    View in: PubMed
    Score: 0.133
  22. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol. 2013 Apr; 23(2):109-14.
    View in: PubMed
    Score: 0.133
  23. Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning. Med Dosim. 2013; 38(3):298-303.
    View in: PubMed
    Score: 0.133
  24. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35.
    View in: PubMed
    Score: 0.132
  25. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol. 2013 Feb 20; 31(6_suppl):248.
    View in: PubMed
    Score: 0.132
  26. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.132
  27. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.127
  28. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012 Apr; 103(1):12-7.
    View in: PubMed
    Score: 0.124
  29. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
    View in: PubMed
    Score: 0.123
  30. Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. J Clin Oncol. 2012 Feb 10; 30(5_suppl):272.
    View in: PubMed
    Score: 0.123
  31. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2012 Feb 10; 30(5_suppl):264.
    View in: PubMed
    Score: 0.123
  32. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37.
    View in: PubMed
    Score: 0.112
  33. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study. Onkologie. 2010; 33(4):169-73.
    View in: PubMed
    Score: 0.108
  34. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
    View in: PubMed
    Score: 0.108
  35. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2.
    View in: PubMed
    Score: 0.108
  36. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 01; 28(7):1106-11.
    View in: PubMed
    Score: 0.107
  37. Bladder-sparing approaches to invasive disease. World J Urol. 2006 Nov; 24(5):517-29.
    View in: PubMed
    Score: 0.085
  38. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):294-303.
    View in: PubMed
    Score: 0.060
  39. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743.
    View in: PubMed
    Score: 0.054
  40. Reply by Authors. J Urol. 2019 10; 202(4):821-822.
    View in: PubMed
    Score: 0.052
  41. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol. 2019 04; 201(4):721-727.
    View in: PubMed
    Score: 0.051
  42. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019 01 01; 37(1):44-51.
    View in: PubMed
    Score: 0.049
  43. Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. Med Phys. 2018 Jul 14.
    View in: PubMed
    Score: 0.048
  44. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Pract Radiat Oncol. 2018 May - Jun; 8(3):206-212.
    View in: PubMed
    Score: 0.046
  45. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106.
    View in: PubMed
    Score: 0.046
  46. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 05; 18(3):37-43.
    View in: PubMed
    Score: 0.044
  47. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017 03 07; 62(5):1644-1660.
    View in: PubMed
    Score: 0.044
  48. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017 Apr; 56(4):575-581.
    View in: PubMed
    Score: 0.043
  49. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
    View in: PubMed
    Score: 0.043
  50. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654.
    View in: PubMed
    Score: 0.043
  51. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053.
    View in: PubMed
    Score: 0.042
  52. SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. Med Phys. 2016 Jun; 43(6):3683.
    View in: PubMed
    Score: 0.042
  53. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):454-464.
    View in: PubMed
    Score: 0.040
  54. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):444-453.
    View in: PubMed
    Score: 0.040
  55. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9.
    View in: PubMed
    Score: 0.040
  56. SU-E-T-457: Impact of Interfractional Variations On Anterior Vs. Lateral-Field Proton Therapy of Prostate Cancer. Med Phys. 2015 Jun; 42(6):3439.
    View in: PubMed
    Score: 0.039
  57. TU-EF-304-05: Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE-Weighted Rectal Dose. Med Phys. 2015 Jun; 42(6):3615.
    View in: PubMed
    Score: 0.039
  58. SU-E-J-150: Impact of Intrafractional Prostate Motion On the Accuracy and Efficiency of Prostate SBRT Delivery: A Retrospective Analysis of Prostate Tracking Log Files. Med Phys. 2014 Jun; 41(6):190-191.
    View in: PubMed
    Score: 0.036
  59. SU-E-T-616: Comparison of Plan Dose Accuracy for Anterior Vs. Lateral Fields in Proton Therapy of Prostate Cancer. Med Phys. 2014 Jun; 41(6):369.
    View in: PubMed
    Score: 0.036
  60. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S30.
    View in: PubMed
    Score: 0.033
  61. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6.
    View in: PubMed
    Score: 0.033
  62. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013 Jan; 106(1):64-8.
    View in: PubMed
    Score: 0.033
  63. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013 May; 63(5):823-9.
    View in: PubMed
    Score: 0.033
  64. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e13-9.
    View in: PubMed
    Score: 0.031
  65. Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):22.
    View in: PubMed
    Score: 0.031
  66. Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. J Clin Oncol. 2012 Feb 10; 30(5_suppl):324.
    View in: PubMed
    Score: 0.031
  67. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
    Score: 0.031
  68. Developing a national radiation oncology registry: From acorns to oaks. Pract Radiat Oncol. 2012 Jan-Mar; 2(1):10-7.
    View in: PubMed
    Score: 0.030
  69. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e25-31.
    View in: PubMed
    Score: 0.029
  70. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.